Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy

Area of Science:

• Oncology
• Radiopharmaceutical Therapy
• Immunotherapy

Background:

• Prostate cancer (PCa) management includes PSMA-targeted radiopharmaceutical therapy (RPT), notably [177Lu]Lu-PSMA-617, which has shown efficacy in metastatic castration-resistant PCa.
• However, treatment resistance and the immunosuppressive tumor microenvironment in PCa limit the effectiveness of RPT and conventional immunotherapy.
• Combining these modalities offers a potential strategy to enhance anti-tumor responses.

Purpose of the Study:

• To explore the scientific rationale for combining PSMA-targeted RPT with immune checkpoint inhibitors (ICIs) in prostate cancer.
• To review existing preclinical and clinical evidence supporting this combination therapy.
• To discuss future research directions and clinical integration strategies.

Main Methods:

• Literature review of preclinical studies investigating the synergistic effects of RPT and ICIs.
• Analysis of clinical trial data evaluating the safety and efficacy of combined RPT and ICI treatments.
• Exploration of the immunological mechanisms underlying the combination's potential benefits.

Main Results:

• Preclinical data suggest that RPT can modulate the tumor microenvironment, potentially enhancing ICI efficacy.
• Early clinical evidence indicates that combining RPT with ICIs may improve patient outcomes in metastatic castration-resistant PCa.
• Specific immune checkpoint inhibitors, such as those targeting PD-1/PD-L1, are being investigated in combination with RPT.

Conclusions:

• The combination of PSMA-targeted RPT and immune checkpoint blockade presents a promising therapeutic strategy for prostate cancer.
• Further clinical investigation is warranted to optimize treatment protocols and confirm long-term efficacy and safety.
• This combined approach holds potential to overcome resistance mechanisms and improve survival for patients with advanced PCa.